Urginafect Oral Suspension 

Active Ingredients:
Solfenacin succinate 1 mg/ml Oral Suspension 

 

Therapeutic indications 
-Neurogenic detrusor overactivity: Urginafect oral suspension is indicated for the treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 2 to 18 years. 
-Overactive bladder in adults: Urginafect oral suspension is indicated for symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder (OAB) syndrome.